Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Spinal zap trial aims to ease Parkinson's stoop

NCT ID NCT06291051

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether electrical spinal cord stimulation is safe for people with Parkinson's disease who have a painful, bent-forward posture called camptocormia. Six participants will receive the stimulation and be monitored for side effects for about 10-11 months. The goal is to see if this approach can help with pain and posture without major risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 6 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Parkinson's disease validated according to UKPDSBB clinical criteria * Camptocormia defined by a total camptocormia angle (ACT) \> 30° or a greater camptocormia angle (ACS) \> 45° * Camptocormia established for less than 2 years or recently worsening for less than 1 year. * Persistent camptocormia despite optimal drug treatment at the time of inclusion * Pain associated with abnormal posture: VAS ≥ 4/10 during the last 3 months * Stable antiparkinsonian treatment for 4 weeks * Treatment with co-analgesics stable for 4 weeks * Criteria relating to regulation: * Major person * Affiliation to a social security scheme * Adult who has read and understood the information letter and signed the consent form * Women: * Of childbearing age (defined by the CTFG as a fertile woman, after menarche and until menopause, except in cases of permanent sterility (including hysterectomy, bilateral salpingectomy or bilateral oophorectomy)): * using effective contraception according to the WHO (combined hormonal contraception (containing estrogens and progestins), progestin-only contraception, intrauterine device IUD), male or female condoms) for 1 month before inclusion and during the study And, * presenting a negative urine pregnancy test at inclusion - Menopause: menopause according to the CTFG is defined as the absence of periods for 12 months without any other medical cause before the inclusion visit. An elevated follicle-stimulating hormone (FSH) level in the postmenopausal interval can be used to confirm a postmenopausal state in women who are not using hormonal contraception or hormone replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. Exclusion Criteria: * Atypical parkinsonian syndrome * Contraindication to surgery and anesthetic products * Uncontrolled diabetes * Systemic or local infection * Major cognitive disorders: MOCA \< 25 * Severe psychosis associated with Parkinson's disease * Severe depressive syndrome: MADRS \> 35 * Patient with deep brain stimulation * Patient with a cardiac pacemaker * Patient currently being treated by diathermy or to be treated by diathermy * Severe substance use disorders (alcohol, drugs, medication) * Contraindication to MRI * Obstacle to the placement of a dorsal epidural electrode * Dorsal myelopathy * Severe associated scoliosis * Severe camptocormia defined by an ACT \> 80° * Severe alteration of somesthetic evoked potentials (ESP) in the lower limbs * Pregnant or parturient or breastfeeding woman or proven absence of contraception * Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection/under guardianship or curatorship * History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or preventing them from giving informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU CAEN

    RECRUITING

    Caen, 14033, France

  • Chu Amiens

    RECRUITING

    Amiens, 80054, France

  • Chu Lille

    RECRUITING

    Lille, 59037, France

  • Chu Rouen

    RECRUITING

    Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.